US 10060921
Methods of treating transthyretin (TTR) mediated amyloidosis
granted A61KA61K31/423A61K31/603
Quick answer
US patent 10060921 (Methods of treating transthyretin (TTR) mediated amyloidosis) held by Alnylam Pharmaceuticals, Inc. expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K31/423, A61K31/603, A61K31/713, A61K45/06